Rac1/cdc42 Antibody - #AF7828

>>买2送1 进行中>>
>>赠JD卡 进行中>>
(4)   (4)  
产品: Rac1/cdc42 抗体
货号: AF7828
描述: Rabbit polyclonal antibody to Rac1/cdc42
应用: WB
文献验证: WB
反应: Human, Mouse, Rat
预测: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
蛋白号: P63000 | P60953
RRID: AB_2844192

浏览相似产品>>

   规格 价格 库存
 50ul RMB¥ 1250 现货
 100ul RMB¥ 2300 现货
 200ul RMB¥ 3000 现货

货期: 当天发货

联系销售
相关下载
MS Report
HPLC Report
MSDS
说明书
COA
实验方案
WB Handbook
IHC Protocol
IF/ICC Protocol

产品描述

来源:
Rabbit
应用:
WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: 适用于变性蛋白样本的免疫印迹检测. IHC: 适用于组织样本的石蜡(IHC-p)或冰冻(IHC-f)切片样本的免疫组化/荧光检测. IF/ICC: 适用于细胞样本的荧光检测. ELISA(peptide): 适用于抗原肽的ELISA检测.

反应:
Human, Mouse, Rat
克隆:
Polyclonal
特异性:
Rac1/cdc42 Antibody detects endogenous levels of total Rac1/cdc42.
RRID:
AB_2844192
引用格式: Affinity Biosciences Cat# AF7828, RRID:AB_2844192.
偶联:
Unconjugated.
纯化:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
别名:

展开/折叠

CDC42; CDC42_HUMAN; CDC42Hs; Cell division control protein 42 homolog; Cell division cycle 42 (GTP binding protein 25kDa); Cell division cycle 42; dJ224A6.1.1 (cell division cycle 42 (GTP-binding protein, 25kD)); dJ224A6.1.2 (cell division cycle 42 (GTP-binding protein, 25kD)); G25K; G25K GTP-binding protein; Growth regulating protein; GTP binding protein 25kDa; Small GTP binding protein CDC42; TKS;

抗原和靶标

免疫原:

A synthesized peptide derived from human Rac1/cdc42, corresponding to a region within the internal amino acids.

基因/基因ID:
RAC1(5879) | CDC42(998)

研究领域

· Cellular Processes > Transport and catabolism > Endocytosis.   (View pathway)

· Cellular Processes > Transport and catabolism > Phagosome.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Tight junction.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Neurodegenerative diseases > Amyotrophic lateral sclerosis (ALS).

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Bacterial > Epithelial cell signaling in Helicobacter pylori infection.

· Human Diseases > Infectious diseases: Bacterial > Pathogenic Escherichia coli infection.

· Human Diseases > Infectious diseases: Bacterial > Shigellosis.

· Human Diseases > Infectious diseases: Bacterial > Salmonella infection.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer.   (View pathway)

· Human Diseases > Cardiovascular diseases > Viral myocarditis.

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Development > Axon guidance.   (View pathway)

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway.   (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis.   (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration.   (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Digestive system > Pancreatic secretion.

文献引用

1). Combination of dihydroartemisinin and resveratrol effectively inhibit cancer cell migration via regulation of DLC1/TCTP/Cdc42 pathway. Food & Function, 2020 (PubMed: 33150340) [IF=5.1]

Application: WB    Species: Human    Sample: HepG2 and MDA-MB-231 cells

Fig 3 Effects of DHA and RES alone or in combination on DLC1, TCTP and Cdc42 expression. HepG2 and MDA-MB-231 cells were treated with DHA (25 M), RES (50 M) and DHA + RES (25 + 50 M) for 24 h. DLC1, TCTP and Cdc42 levels were detected by western blotting. Bar graphs showed their relative levels to GAPDH.
2). Effective extraction of Xuetongsu and its role in preventing RA synovial hyperplasia by targeting synovial cell migration and apoptosis. Scientific reports, 2024 (PubMed: 39375373) [IF=3.8]
3). IQGAP3 promotes cancer proliferation and metastasis in high‑grade serous ovarian cancer. Oncology Letters, 2020 (PubMed: 32724358) [IF=2.5]

Application: WB    Species: Human    Sample: A2780 and HEY cells

Figure 4. Western blot analysis revealed the changes in protein expression of several proteins following IQGAP3 knockdown using two siRNAs. Both A2780 and HEY cells had an altered protein expression following the knockdown. The alteration in the protein expression included EMT-related proteins (E-CAD, N-CAD, ZEB-1, Vimentin and Snail), apoptosis-related proteins (Caspase-3, Caspase-9, Bcl2 and Bax), proteins associated with DNA damage and chemoresistance (Rad51, p-ATM, ATM, CHK2 and Pgp), and proteins involved in the regulation and mechanism of the effect of IQGAP3 (CDC42, PI3K, p-AKT, AKT, p-mTOR and mTOR). β-actin was used as the internal control. IQGAP3, IQ motif containing GTPase Activating Protein 3; EMT, epithelial-to-mesenchymal transition; p-, phosphorylated; E-CAD, E-cadherin; N-CAD, N-cadherin; Pgp, phosphoglycolate phosphatase; Rad51, RAD51 recombinase; CHK2, checkpoint kinase 2; NC, negative control; si, small interfering RNA; ZEB-1, zinc finger E-Box binding homeobox 1.
4). miR-29a regulated ER-positive breast cancer cell growth and invasion and is involved in the insulin signaling pathway. Oncotarget, 2017 (PubMed: 28427228)

Application: WB    Species: human    Sample: MCF-7

Figure 5: Effect of miR-29a on the insulin signaling pathways. (A) IGF-1R, CDC42, p85α, p-ERK and ERK mRNA levels were determined by qPCR in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. (B, C) Western blotting analysis was performed to monitor IGF-1R, CDC42, p85α, p-ERK and ERK expression in ER-positive cells transfected with a miR-29a mimic or miR-29a inhibitor. The results showed that ERK, CDC42 and p85α are the target genes of miR-29a; however, miR-29a promotes breast cancer cell growth and proliferation mainly by activating ERK phosphorylation.

限制条款

产品的规格、报价、验证数据请以官网为准，官网链接：www.affbiotech.com | www.affbiotech.cn（简体中文）| www.affbiotech.jp（日本語）

产品的数据信息为Affinity所有，未经授权不得收集Affinity官网数据或资料用于商业用途，对抄袭产品数据的行为我们将保留诉诸法律的权利。

产品相关数据会因产品批次、产品检测情况随时调整，如您已订购该产品，请以订购时随货说明书为准，否则请以官网内容为准，官网内容有改动时恕不另行通知。

Affinity保证所销售产品均经过严格质量检测。如您购买的商品在规定时间内出现问题需要售后时，请您在Affinity官方渠道提交售后申请。

产品仅供科学研究使用。不用于诊断和治疗。 

产品未经授权不得转售。

Affinity Biosciences将不会对在使用我们的产品时可能发生的专利侵权或其他侵权行为负责。Affinity Biosciences, Affinity Biosciences标志和所有其他商标所有权归Affinity Biosciences LTD.